Before she became a medical writer, Claire studied at the University of Cambridge, where she achieved a first class BA in Natural Sciences and was awarded the Seraphim Prize for Biochemistry. She stayed on at Cambridge to complete her PhD in the Department of Clinical Biochemistry, before moving to Barts and The London School of Medicine and Dentistry as a post-doctoral research assistant. During her time in academic research, Claire found that she particularly enjoyed writing, presenting and publishing her work; becoming a professional medical writer was a natural next step, and she hasn't looked back since!

As a medical writer, Claire has worked in a broad range of therapy areas including cardiology, pulmonology, gastroenterology and women’s health, and has gained particular expertise in pulmonary hypertension and heart failure. She has provided medical writing support for peer-reviewed publications (including co-authorship of systematic reviews) and has developed meeting materials, congress reports and strategic publication plans. She has also gained experience of regulatory writing through the development of EU risk management plans and updates of periodic benefit–risk evaluation reports.

An overview of some of Claire's published work (spanning both her academic research and medical writing careers) is shown below.

Selected publications

Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide.

Hungin APS, Mulligan C, Pot B, Whorwell P, Agreus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy J-M, Rubin G, Winchester C, de Wit N, for the European Society for Primary Care Gastroenterology.

Aliment Pharmacol Ther 2013; 38: 864–86.

Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review.

Mulligan C, Beghetti M.

Pediatr Crit Care Med 2012; 13: 472–80.

Riociguat.

Mulligan C.

Drugs Fut 2009; 34: 468.

DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome.

Canzonetta C, Mulligan C, Deutsch S, Ruf S, O'Doherty A, Lyle R, Borel C, Lin-Marq N, Delom F, Groet J, Schnappauf F, De Vita S, Averill S, Priestley JV, Martin JE, Shipley J, Denyer G, Epstein CJ, Fillat C, Estivill X, Tybulewicz VL, Fisher EM, Antonarakis SE, Nizetic D.

Am J Hum Genet 2008; 83: 388–400.

An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes.

O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, Sesay A, Modino S, Vanes L, Hernandez D, Linehan JM, Sharpe PT, Brandner S, Bliss TV, Henderson DJ, Nizetic D, Tybulewicz VL, Fisher EM.

Science 2005; 309: 2033–7.

Microarray Analysis of Insulin and IGF-1 Receptor Signaling Reveals the Selective Upregulation of the Mitogen Heparin-Binding EGF-like Growth Factor by IGF-1.

Mulligan C, Rochford J, Denyer G, Stephens R, Yeo G, Freeman T, Siddle K, O'Rahilly S.

J Biol Chem 2002; 277: 42480–7.